Danaher Corp (DHR) KPIs and segments
Close on Nov 18, 2026Market cap $160.81BP/E 37.4Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Danaher · năm tài chính kết thúc December 31 (Fiscal quarters Q1–Q3 end on the Friday nearest the calendar quarter-end; Q3 2026 ended September 25, 2026; FY2025 ended December 31, 2025)
Nhìn nhanh KPI của Danaher: 77 chỉ số vận hành, trong đó có Total Company Core Sales Growth (Non-GAAP), Biotechnology — Core Sales Growth và Life Sciences — Core Sales Growth, lấy từ 132 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diagnostics($M)6 | 2,882 | 2,466 | 2,417 | 2,720 | 2,463 | 2,309 | 2,449 | 2,637 | 2,363 | 2,260 | 2,527 | 2,716 | |
Recurring revenue($M) | 2,533 | 2,210 | 2,186 | 2,363 | 2,211 | 2,062 | 2,223 | 2,295 | 2,127 | 2,003 | 2,294 | 2,369 | |
North America($M) | 1,439 | 1,132 | 1,265 | 1,310 | 1,228 | 1,064 | 1,318 | 1,323 | 1,157 | 1,042 | 1,337 | 1,348 | |
High-growth markets($M) | 861 | 811 | 635 | 815 | 721 | 746 | 640 | 768 | 737 | 743 | 685 | 836 | |
Western Europe($M) | 474 | 430 | 431 | 484 | 417 | 405 | 400 | 433 | 368 | 380 | 406 | 423 | |
Nonrecurring revenue($M) | 349 | 256 | 231 | 357 | 252 | 247 | 226 | 342 | 236 | 257 | 233 | 347 | |
Other developed markets($M) | 108 | 93 | 86 | 111 | 97 | 94 | 91 | 113 | 101 | 95 | 99 | 109 | |
Life Sciences($M)6 | 1,865 | 1,879 | 1,737 | 2,085 | 1,792 | 1,777 | 1,680 | 2,032 | 1,782 | 1,770 | 1,745 | 1,930 | |
Recurring revenue($M) | 1,282 | 1,268 | 1,203 | 1,278 | 1,216 | 1,214 | 1,136 | 1,261 | 1,228 | 1,208 | 1,192 | 1,155 | |
North America($M) | 751 | 759 | 689 | 807 | 728 | 762 | 721 | 837 | 796 | 785 | 781 | 806 | |
Nonrecurring revenue($M) | 583 | 611 | 534 | 807 | 576 | 563 | 544 | 771 | 554 | 562 | 553 | 775 | |
High-growth markets($M) | 571 | 573 | 499 | 621 | 542 | 503 | 458 | 583 | 501 | 495 | 467 | 559 | |
Western Europe($M) | 411 | 421 | 408 | 510 | 392 | 394 | 378 | 463 | 365 | 374 | 372 | 424 | |
Other developed markets($M) | 132 | 126 | 141 | 147 | 130 | 118 | 123 | 149 | 120 | 116 | 125 | 141 | |
Biotechnology($M)6 | 1,807 | 1,920 | 1,797 | 2,033 | 1,798 | 1,850 | 1,612 | 1,869 | 1,653 | 1,713 | 1,524 | 1,759 | |
Recurring revenue($M) | 1,584 | 1,722 | 1,642 | 1,683 | 1,590 | 1,694 | 1,457 | 1,549 | 1,422 | 1,478 | 1,309 | 1,462 | |
Western Europe($M) | 605 | 689 | 726 | 697 | 587 | 708 | 566 | 596 | 587 | 567 | 546 | 568 | |
High-growth markets($M) | 594 | 574 | 490 | 591 | 498 | 448 | 439 | 563 | 485 | 458 | 385 | ||
North America($M) | 550 | 583 | 524 | 639 | 624 | 612 | 543 | 613 | 503 | 607 | 514 | 632 | |
Nonrecurring revenue($M) | 223 | 198 | 155 | 350 | 208 | 156 | 155 | 320 | 231 | 235 | 215 | 297 | |
Other developed markets($M) | 58 | 74 | 57 | 106 | 89 | 82 | 64 | 97 | 78 | 81 | 79 | ||
Recurring revenue($M) | 5,399 | 5,200 | 5,031 | 5,324 | 5,017 | 4,970 | 4,816 | 5,105 | 4,777 | 4,689 | 4,795 | 4,986 | |
Nonrecurring revenue($M) | 1,155 | 1,065 | 920 | 1,514 | 1,036 | 966 | 925 | 1,433 | 1,021 | 1,054 | 1,001 | 1,419 | |
North America($M) | 2,740 | 2,474 | 2,478 | 2,756 | 2,580 | 2,438 | 2,582 | 2,773 | 2,456 | 2,434 | 2,632 | 2,786 | |
High-growth markets($M) | 2,026 | 1,958 | 1,624 | 2,027 | 1,761 | 1,697 | 1,537 | 1,914 | 1,723 | 1,696 | 1,537 | 1,854 | |
Western Europe($M) | 1,490 | 1,540 | 1,565 | 1,691 | 1,396 | 1,507 | 1,344 | 1,492 | 1,320 | 1,321 | 1,324 | 1,415 | |
Other developed markets($M) | 298 | 293 | 284 | 364 | 316 | 294 | 278 | 359 | 299 | 292 | 303 | 350 | |
Diagnostics($M) | 614 | 416 | 674 | 713 | 665 | 554 | 718 | 624 | 615 | 556 | 830 | 766 | |
Biotechnology($M) | 477 | 556 | 534 | 540 | 352 | 531 | 441 | 508 | 390 | 462 | 325 | 416 | |
Life Sciences($M) | 259 | 244 | 225 | 336 | 222 | -239 | 201 | 376 | 35 | 233 | 235 | 235 | |
Life Sciences($M) | -44 | -38 | -27 | -57 | -40 | -41 | -48 | -229 | -52 | -50 | -60 | ||
Biotechnology($M) | -56 | -66 | -64 | -115 | -94 | -80 | -81 | -117 | -117 | -111 | -102 | ||
Diagnostics($M) | -155 | -164 | -144 | -195 | -157 | -125 | -115 | -168 | -129 | -126 | -127 | ||
Biotechnology($M) | 35,504 | 36,009 | 36,697 | 37,337 | 37,296 | 37,562 | 36,121 | 34,605 | 37,421 | ||||
Diagnostics($M) | 25,785 | 25,731 | 14,657 | 14,748 | 14,653 | 14,537 | 14,291 | 14,204 | 14,552 | ||||
Life Sciences($M) | 22,645 | 22,593 | 22,873 | 23,112 | 23,179 | 23,397 | 23,396 | 23,211 | 23,730 | ||||
Remaining performance obligations (RPO)($M) | 7,400 | 7,500 | 5,300 | 4,900 | 4,900 | 4,500 | 4,400 | 4,500 | 4,600 | ||||
Total Company Core Sales Growth (Non-GAAP)(%)5 | 3.0% | 3.0% | 0.5% | 2.5% | 3.0% | 1.5% | 0.0% | 1.0% | 0.5% | -3.5% | -4.0% | -11.5% | |
Core Growth ex-Respiratory(%) | 5.5% | 4.5% | 3.0% | 4.0% | 2.5% | 2.0% | 1.0% | ||||||
Contribution / Headwind from Cepheid Respiratory Testing to Total Company Core Sales Growth(%) | 2.5% | 1.5% | 2.5% | 1.5% | -0.5% | 0.5% | 1.0% | ||||||
Base Business Core Sales Growth (Legacy FY2021Q4–FY2023Q4: Base Business ex-COVID Testing & Vx/Tx)(%) | -4.5% | ||||||||||||
Currency Exchange Impact(%) | 0.0% | -1.0% | -3.0% | -2.5% | -1.5% | -2.0% | 1.5% | 0.5% | 0.0% | 1.5% | 0.5% | -1.0% | |
Reported GAAP Sales Growth(%) | 8.5% | 5.5% | 3.5% | 4.5% | 4.5% | 3.5% | -1.0% | 2.0% | 3.0% | -3.0% | -2.5% | -10.0% | |
Biotechnology — Core Sales Growth (%)(%)2 | 5.0% | 2.5% | 7.0% | 6.0% | 6.5% | 6.0% | 7.0% | 8.0% | 0.0% | -7.0% | -17.0% | -22.5% | |
Biotechnology — Currency Exchange Impact(%) | 0.5% | -1.5% | -4.5% | -3.0% | -2.5% | -2.0% | 1.0% | 1.5% | 0.5% | 2.0% | 1.0% | -1.5% | |
Biotechnology — GAAP Sales Growth(%) | 0.5% | 4.0% | 11.5% | 9.0% | 9.0% | 8.0% | 6.0% | 6.5% | -0.5% | -9.0% | -18.0% | -21.0% | |
Life Sciences — Core Sales Growth (%)(%)2 | 4.5% | 5.5% | 0.5% | 0.5% | -1.0% | -2.5% | -4.0% | 1.0% | -2.0% | -5.5% | -3.0% | -4.0% | |
Life Sciences — Currency Exchange Impact(%) | 0.5% | 0.0% | -3.0% | -2.0% | -1.5% | -1.5% | 1.5% | 0.5% | 0.5% | 2.0% | 1.0% | -0.5% | |
Life Sciences — GAAP Sales Growth(%) | 4.0% | 5.5% | 3.5% | 2.5% | 0.5% | 0.5% | -3.5% | 5.5% | 4.5% | -1.5% | 2.0% | -1.0% | |
Diagnostics — Core Sales Growth (%)(%)3 | 0.5% | 2.0% | -4.0% | 2.0% | 3.5% | 2.0% | -1.5% | -2.0% | 5.0% | 3.0% | 7.5% | -8.5% | |
Diagnostics — Price Realization (reflecting China VBP centralized procurement)(%) | -1.0% | -1.5% | -2.0% | -1.5% | -1.0% | -0.5% | 0.5% | ||||||
Diagnostics — Currency Exchange Impact(%) | 0.0% | -1.0% | -2.5% | -2.0% | -1.0% | -0.5% | 1.0% | 1.0% | 0.0% | 1.5% | 1.0% | 0.0% | |
Diagnostics — GAAP Sales Growth(%) | 17.0% | 7.0% | -1.5% | 3.0% | 4.0% | 2.0% | -3.0% | -3.0% | 5.0% | 1.5% | 6.5% | -8.5% | |
Cepheid Respiratory Testing Revenue (GeneXpert 4-in-1 & COVID-19)($M) | 350 | 250 | 500 | 500 | 500 | 300 | 650 | 550 | 425 | 300 | 675 | 650 | |
High-Growth Markets % of Total Sales(%)2 | 31.0% | 31.0% | 27.0% | 29.0% | 29.0% | 27.0% | 30.0% | 30.0% | 27.0% | ||||
High-Growth Markets YoY Sales Growth(%) | 15.0% | 15.0% | 6.0% | 2.0% | -2.0% | -8.0% | -12.0% | ||||||
Developed Markets YoY Sales Growth(%) | 5.0% | 2.0% | 3.0% | 5.0% | 5.0% | -1.0% | 5.0% | -1.0% | 1.0% | ||||
Remaining Performance Obligations / Unfulfilled Backlog($M)2 | 7,400 | 7,500 | 5,300 | 5,200 | 4,900 | 4,900 | 4,500 | 4,300 | 4,400 | 4,500 | 4,600 | 4,700 | |
RPO Expected within Next 12 Months (%)(%) | 41.0% | 41.0% | 48.0% | 47.0% | 46.0% | 46.0% | 48.0% | 47.0% | 49.0% | 52.0% | 51.0% | ||
RPO Expected in Months 13–24 (%)(%) | 26.0% | 26.0% | 26.0% | 26.0% | 28.0% | 28.0% | 26.0% | 27.0% | 26.0% | 25.0% | 25.0% | ||
Total Contract Liabilities — Current & Noncurrent($M)1 | 1,700 | 1,700 | 1,700 | 1,600 | 1,600 | 1,700 | 1,700 | 1,500 | 1,600 | 1,600 | 1,800 | 1,700 | |
Revenue Recognized from Prior Contract Liabilities($M) | 196 | 267 | 537 | 227 | 204 | 272 | 497 | 200 | 199 | 354 | 547 | 200 | |
Equipment Lease Revenue — OTLs & STLs($M) | 147 | 128 | 143 | 123 | 112 | 117 | 114 | 115 | 93 | 95 | 99 | 110 | |
Adjusted Operating Profit — Non-GAAP($M)16 | 1,900 | 1,698 | 1,795 | 1,934 | 1,688 | 1,618 | 1,699 | 1,932 | 1,594 | 1,570 | 1,744 | 1,837 | |
Biotechnology — Adjusted OP($M) | 756 | 787 | 768 | 770 | 669 | 759 | 669 | 721 | 608 | 676 | 543 | 643 | |
Life Sciences — Adjusted OP($M) | 404 | 395 | 377 | 501 | 376 | 343 | 350 | 524 | 404 | 373 | 401 | 436 | |
Diagnostics — Adjusted OP($M) | 831 | 605 | 739 | 750 | 728 | 602 | 766 | 770 | 664 | 604 | 878 | 838 | |
Other / Corporate Unallocated Adjusted Expense($M) | -91 | -89 | -89 | -87 | -85 | -86 | -86 | -83 | -82 | -83 | -78 | -80 | |
Adjusted Operating Profit Margin — Non-GAAP(%) | 29.0% | 27.1% | 30.2% | 28.3% | 27.9% | 27.3% | 29.6% | 29.6% | 27.5% | 27.3% | 30.1% | 28.7% | |
Biotechnology — Adjusted OP Margin(%) | 41.8% | 41.0% | 42.7% | 37.9% | 37.2% | 41.0% | 41.5% | 38.6% | 36.8% | 39.5% | 35.6% | 36.6% | |
Life Sciences — Adjusted OP Margin(%) | 21.7% | 21.0% | 21.7% | 24.0% | 21.0% | 19.3% | 20.8% | 25.8% | 22.7% | 21.1% | 23.0% | 22.6% | |
Diagnostics — Adjusted OP Margin(%) | 28.8% | 24.5% | 30.6% | 27.6% | 29.6% | 26.1% | 31.3% | 29.2% | 28.1% | 26.7% | 34.7% | 30.9% | |
GAAP Operating Margin(%) | 19.0% | 18.0% | 22.6% | 22.0% | 19.1% | 12.8% | 22.2% | 21.8% | 16.5% | 20.3% | 22.6% | 20.9% | |
Biotechnology — Reported GAAP Operating Margin(%) | 26.4% | 29.0% | 29.7% | 26.6% | 19.6% | 28.7% | 27.4% | 27.2% | 23.6% | 27.0% | 21.3% | 23.6% | |
Life Sciences — Reported GAAP Operating Margin(%) | 13.9% | 13.0% | 13.0% | 16.1% | 12.4% | -13.4% | 12.0% | 18.5% | 2.0% | 13.2% | 13.5% | 12.2% | |
Diagnostics — Reported GAAP Operating Margin(%) | 21.3% | 16.9% | 27.9% | 26.2% | 27.0% | 24.0% | 29.3% | 23.7% | 26.0% | 24.6% | 32.8% | 28.2% | |
Core Operating Margin Change (percentage points)(%) | 1.7% | -0.1% | 0.4% | -1.2% | 0.5% | 0.1% | -0.3% | 1.2% | 0.5% | 0.8% | -1.7% | -5.0% | |
Biotechnology — YoY Core Operating Margin Change (percentage points)(%) | 4.9% | 0.3% | 1.4% | -0.6% | 0.8% | 1.7% | 7.0% | 2.9% | -1.5% | -0.7% | -10.7% | -6.9% | |
Life Sciences — YoY Core Operating Margin Change (percentage points)(%) | 1.2% | 2.1% | 1.0% | -1.7% | -2.1% | -1.6% | -2.5% | 3.8% | -0.3% | -3.4% | -1.7% | -2.8% | |
Diagnostics — YoY Core Operating Margin Change (percentage points)(%) | 0.3% | -1.7% | -0.8% | -1.4% | 1.7% | -0.5% | -3.4% | -1.6% | 2.1% | 5.6% | 4.3% | -4.3% | |
Consolidated Adjusted EBITDA (Non-GAAP Supplemental Data)($M)8 | 2,108 | 1,894 | 1,988 | 2,129 | 1,877 | 1,803 | 1,880 | 2,119 | 1,771 | 1,748 | 1,923 | 2,015 | |
Biotechnology — Adjusted EBITDA($M) | 800 | 827 | 808 | 809 | 707 | 797 | 703 | 759 | 644 | 711 | 585 | 686 | |
Life Sciences — Adjusted EBITDA($M) | 452 | 443 | 425 | 549 | 423 | 388 | 395 | 568 | 448 | 414 | 439 | 473 | |
Diagnostics — Adjusted EBITDA($M) | 944 | 712 | 841 | 856 | 829 | 702 | 866 | 872 | 759 | 704 | 975 | 935 | |
Other / Corporate — Adjusted EBITDA($M) | -88 | -88 | -86 | -85 | -82 | -84 | -84 | -80 | -80 | -81 | -76 | -79 | |
Biên Adjusted EBITDA toàn công ty (Adjusted EBITDA Margin)(%) | 32.2% | 30.2% | 33.4% | 31.1% | 31.0% | 30.4% | 32.7% | 32.4% | 30.5% | 30.4% | 33.2% | 31.5% | |
Biotechnology — Biên Adjusted EBITDA(%) | 44.3% | 43.1% | 45.0% | 39.8% | 39.3% | 43.1% | 43.6% | 40.6% | 39.0% | 41.5% | 38.4% | 39.0% | |
Life Sciences — Biên Adjusted EBITDA(%) | 24.2% | 23.6% | 24.5% | 26.3% | 23.6% | 21.8% | 23.5% | 28.0% | 25.1% | 23.4% | 25.2% | 24.5% | |
Diagnostics — Biên Adjusted EBITDA(%) | 32.8% | 28.9% | 34.8% | 31.5% | 33.7% | 30.4% | 35.4% | 33.1% | 32.1% | 31.2% | 38.6% | 34.4% | |
Segment Intangibles Amortization($M)6 | 513 | 463 | 434 | 428 | 433 | 426 | 410 | 408 | 414 | 402 | 407 | 380 | |
Biotechnology — Intangible Assets Amortization($M) | 227 | 231 | 234 | 230 | 231 | 228 | 213 | 213 | 218 | 214 | 218 | 215 | |
Life Sciences — Intangible Assets Amortization($M) | 153 | 151 | 152 | 151 | 154 | 150 | 149 | 148 | 147 | 140 | 141 | 116 | |
Diagnostics — Intangible Assets Amortization($M) | 133 | 81 | 48 | 47 | 48 | 48 | 48 | 47 | 49 | 48 | 48 | 49 | |
Biotechnology — Intangibles Amortization % of Segment Sales (MD&A)(%) | 12.6% | 12.0% | 13.0% | 12.8% | 12.3% | 13.2% | 13.2% | 12.5% | 14.3% | ||||
Life Sciences — Intangibles Amortization % of Segment Sales (MD&A)(%) | 8.2% | 8.0% | 8.8% | 8.6% | 8.4% | 8.9% | 8.2% | 7.9% | 8.1% | ||||
Diagnostics — Intangibles Amortization % of Segment Sales (MD&A)(%) | 4.6% | 3.3% | 2.0% | 1.9% | 2.1% | 2.0% | 2.1% | 2.1% | 1.9% | ||||
Segment Depreciation($M)7 | 208 | 196 | 193 | 195 | 189 | 185 | 181 | 187 | 177 | 178 | 179 | 178 | |
Biotechnology — Depreciation($M) | 44 | 40 | 40 | 39 | 38 | 38 | 34 | 38 | 36 | 35 | 42 | 43 | |
Life Sciences — Depreciation($M) | 48 | 48 | 48 | 48 | 47 | 45 | 45 | 44 | 44 | 41 | 38 | 37 | |
Diagnostics — Depreciation (including diagnostic instruments placed in hospitals)($M) | 113 | 107 | 102 | 106 | 101 | 100 | 100 | 102 | 95 | 100 | 97 | 97 | |
Other / Corporate — Depreciation($M) | 3 | 1 | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | |
Biotechnology — Depreciation % of Segment Sales (MD&A)(%) | 2.4% | 2.1% | 2.2% | 2.1% | 2.1% | 2.1% | 2.2% | 2.0% | 2.8% | ||||
Life Sciences — Depreciation % of Segment Sales (MD&A)(%) | 2.6% | 2.6% | 2.8% | 2.6% | 2.5% | 2.7% | 2.5% | 2.3% | 2.2% | ||||
Diagnostics — Depreciation % of Segment Sales (MD&A)(%) | 3.9% | 4.3% | 4.2% | 4.1% | 4.3% | 4.1% | 4.0% | 4.4% | 3.8% | ||||
Other Segment Items Under ASU 2023-07 — Total 3 Segments($M)5 | 4,350 | 4,391 | 3,894 | 4,614 | 4,094 | 4,049 | 3,792 | ||||||
Biotechnology — Other Segment Items($M) | 1,007 | 1,093 | 989 | 1,224 | 1,091 | 1,053 | 924 | ||||||
Life Sciences — Other Segment Items($M) | 1,405 | 1,436 | 1,312 | 1,536 | 1,369 | 1,389 | 1,285 | ||||||
Diagnostics — Other Segment Items($M) | 1,938 | 1,862 | 1,593 | 1,854 | 1,634 | 1,607 | 1,583 | ||||||
Corporate Unallocated Other Items($M) | 102 | 88 | 86 | 85 | 82 | 84 | 84 | ||||||
Total Other Segment Items($M) | 4,452 | 4,479 | 3,980 | 4,699 | 4,176 | 4,133 | 3,876 | ||||||
Adjusted Gross Profit Margin — Non-GAAP(%)2 | 60.6% | 58.4% | 60.3% | 58.2% | 58.2% | 59.3% | 61.4% | 59.5% | 58.7% | 59.7% | |||
GAAP Gross Profit Margin(%) | 58.5% | 57.6% | 60.3% | 58.0% | 58.2% | 59.3% | 61.2% | 59.5% | 58.7% | 59.7% | |||
Adjusted Cost of Sales — Non-GAAP($M) | 2,581 | 2,608 | 2,360 | 2,858 | 2,530 | 2,413 | 2,215 | 2,648 | 2,397 | 2,315 | |||
Adjusted R&D — Non-GAAP($M)1 | 433 | 412 | 387 | 438 | 378 | 403 | 379 | 442 | 383 | 391 | |||
Adjusted R&D % of Sales(%) | 6.6% | 6.6% | 6.5% | 6.4% | 6.2% | 6.8% | 6.6% | 6.8% | 6.6% | 6.8% | |||
Adjusted SG&A — Non-GAAP($M)1 | 1,640 | 1,547 | 1,409 | 1,608 | 1,457 | 1,502 | 1,448 | 1,516 | 1,424 | 1,467 | |||
Adjusted SG&A % of Sales(%) | 25.0% | 24.7% | 23.7% | 23.5% | 24.1% | 25.3% | 25.2% | 23.2% | 24.6% | 25.5% | |||
Adjusted Net Earnings — Non-GAAP($M)1 | 1,494 | 1,375 | 1,463 | 1,586 | 1,349 | 1,292 | 1,356 | 1,556 | 1,246 | 1,274 | |||
Adjusted Diluted Net Earnings Per Share — Non-GAAP($) | 2.11 | 1.94 | 2.06 | 2.23 | 1.89 | 1.80 | 1.88 | 2.14 | 1.71 | 1.72 | |||
Free Cash Flow — Non-GAAP($M)3 | 1,632 | 1,265 | 1,085 | 1,769 | 1,370 | 1,094 | 1,060 | 1,504 | 1,226 | 1,131 | 1,448 | 1,163 | |
FCF to Adjusted Net Earnings Conversion Ratio(×) | 1.35 | 1.45 | 1.05 | 1.50 | 1.51 | 1.97 | 1.11 | 1.38 | 1.50 | 1.25 | 1.33 | 1.04 | |
OCF to GAAP Net Earnings Conversion Ratio(×) | 1.56 | 1.76 | 1.28 | 1.79 | 1.83 | 2.41 | 1.36 | 1.86 | 1.85 | 1.56 | 1.60 | 1.42 | |
Payments for Repurchase of Common Stock($M) | 0 | 894 | 0 | 0 | 2,010 | 0 | 1,078 | 809 | 640 | 4,530 | 0 | 0 | |
Finished Goods Inventory($M) | 1,676 | 1,813 | 1,360 | 1,287 | 1,373 | 1,383 | 1,272 | 1,145 | 1,353 | 1,352 | 1,296 | 1,282 | |
Work in Process Inventory($M) | 542 | 537 | 504 | 469 | 526 | 525 | 517 | 465 | 498 | 491 | 509 | 459 | |
Raw Materials Inventory($M) | 916 | 910 | 744 | 733 | 775 | 781 | 743 | 720 | 827 | 828 | 840 | 853 | |
Consolidated Amortization of Intangible Assets — XBRL($M)1 | 513 | 463 | 434 | 428 | 433 | 426 | 410 | 408 | 414 | 402 | 407 | 380 | |
Consolidated Depreciation — XBRL($M) | 208 | 196 | 193 | 195 | 189 | 185 | 181 | 187 | 177 | 178 | 179 | 178 | |
Masimo — Non-Invasive Technology Boards & Instruments Shipped | 76,800 | 69,300 | 66,000 | 63,100 | 72,200 | 65,100 | 60,500 | 58,600 | 50,400 | 58,500 | |||
Masimo — Healthcare Revenue($M)2 | 404 | 413 | 372 | 371 | 372 | 368 | 343 | 344 | |||||
Masimo — Direct & Distribution Channel Revenue($M) | 365 | 377 | 330 | 339 | 331 | 326 | 311 | 316 | 311 | ||||
Masimo — OEM Channel Revenue($M) | 38.6 | 35.6 | 41.4 | 32.4 | 40.7 | 42.1 | 32.6 | 28.2 | 28.8 | ||||
Masimo — Unrecognized Contract Revenue / RPO($M) | 1,952 | 1,794 | 1,714 | 1,720 | 1,762 | 1,773 | 1,652 | 1,602 | 1,508 | 1,497 | |||
Masimo — Healthcare Gross Profit($M)3 | 251 | 247 | 231 | 233 | 234 | 168 | 212 | 207 | |||||
Masimo — R&D Expense($M) | 30 | 32.1 | 30.5 | 29.9 | 33.9 | 68 | 37.3 | 39.1 | |||||
Masimo — SG&A Expense($M) | 143 | 131 | 116 | 139 | 119 | 170 | 137 | 126 | |||||
Masimo — Operating Income($M) | 77.4 | 83.9 | 83.6 | 64.5 | 78 | -70.3 | 38.2 | 41.9 | |||||
openFDA — Total FDA 510(k) Medical Device Clearances for the Danaher Ecosystem (Monthly / Quarterly / Annual)8 | 8 | 4 | 8 | 1 | 7 | 5 | 7 | 6 | 7 | 11 | 7 | 8 | |
Beckman Coulter (Diagnostics & Life Sciences) — FDA 510(k) Clearances | 1 | 0 | 4 | 1 | 6 | 1 | 2 | 1 | 5 | 8 | 5 | 3 | |
Cepheid (GeneXpert Molecular Diagnostics) — FDA 510(k) Clearances | 3 | 0 | 2 | 0 | 0 | 2 | 4 | 3 | 0 | 1 | 0 | 2 | |
Radiometer Medical (Blood Gas & Acute Care Analyzers) — FDA 510(k) Clearances | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
Leica Biosystems & Microsystems (Pathology & Microscopy) — FDA 510(k) Clearances | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
HemoCue (Point-of-Care POC Hematology Testing) — FDA 510(k) Clearances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — FDA 510(k) Clearances | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | |
Masimo Corporation (Pulse Oximetry & Non-Invasive Patient Monitoring) — FDA 510(k) Clearances | 2 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 3 | |
U.S. Industry Benchmark — U.S. Industry Total 510(k) Clearances | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
openFDA — Total FDA PMA (Premarket Approval & Supplements) High-Risk Device Approvals for the Danaher Ecosystem5 | 0 | 1 | 0 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | |
Beckman Coulter — FDA PMA Approvals | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | |
Cepheid — FDA PMA Approvals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Leica Biosystems — FDA PMA Approvals | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
Masimo Corporation — FDA PMA Approvals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
U.S. Industry Benchmark — U.S. Industry Total PMA Approvals | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
openFDA — Device Recall Events for the Danaher Ecosystem on the FDA Portal8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Beckman Coulter (Diagnostics & Life Sciences) — Recall Events on openFDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cepheid (GeneXpert Molecular Diagnostics) — Recall Events on openFDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Radiometer Medical (Blood Gas & Acute Care Analyzers) — Recall Events on openFDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Leica Biosystems & Microsystems (Pathology & Microscopy) — Recall Events on openFDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
HemoCue (Point-of-Care POC Hematology Testing) — Recall Events on openFDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — Recall Events on openFDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Masimo Corporation (Pulse Oximetry & Non-Invasive Patient Monitoring) — Recall Events on openFDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
openFDA — Recall Enforcement Reports for the Danaher Ecosystem | 7 | 5 | 7 | 15 | 17 | 13 | 11 | 13 | 17 | 7 | 7 | 5 | |
openFDA — MAUDE Adverse Event Reports for the Danaher Ecosystem7 | 935 | 467 | 365 | 326 | 284 | 314 | 319 | 268 | 320 | 246 | 269 | 247 | |
Beckman Coulter (Diagnostics & Life Sciences) — MAUDE Adverse Event Reports | 541 | 154 | 187 | 174 | 160 | 206 | 205 | 168 | 222 | 143 | 169 | 143 | |
Cepheid (GeneXpert Molecular Diagnostics) — MAUDE Adverse Event Reports | 3 | 3 | 3 | 13 | 7 | 8 | 15 | 10 | 5 | 5 | 10 | 7 | |
Radiometer Medical (Blood Gas & Acute Care Analyzers) — MAUDE Adverse Event Reports | 25 | 35 | 36 | 27 | 36 | 37 | 47 | 21 | 32 | 17 | 19 | 18 | |
Leica Biosystems & Microsystems (Pathology & Microscopy) — MAUDE Adverse Event Reports | 10 | 21 | 12 | 24 | 20 | 22 | 17 | 23 | 23 | 16 | 23 | 27 | |
HemoCue (Point-of-Care POC Hematology Testing) — MAUDE Adverse Event Reports | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — MAUDE Adverse Event Reports | 8 | 6 | 7 | 10 | 3 | 5 | 14 | 1 | 1 | 4 | 10 | 4 | |
Masimo Corporation (Pulse Oximetry & Non-Invasive Patient Monitoring) — MAUDE Adverse Event Reports | 348 | 248 | 120 | 78 | 58 | 36 | 21 | 45 | 37 | 61 | 37 | 48 | |
USAspending.gov — Federal Contract Obligations($M)7 | 60.4 | 32.6 | 44.4 | 85.8 | 39.6 | 37.3 | 47.9 | 99.3 | 93.2 | 34.1 | 34.2 | 95.3 | |
Cepheid — U.S. Federal Contracts (GeneXpert test supplies for the VA hospital system & DoD)($M) | 11.6 | 17.7 | 13.4 | 32.5 | 17.0 | 15.2 | 18.9 | 32.6 | 44.0 | 3.88 | 16.5 | 33.2 | |
Beckman Coulter — U.S. Federal Contracts($M) | 8.44 | 1.97 | 17.0 | 47.3 | 3.02 | -0.01 | 19.5 | 52.8 | 10.1 | 8.57 | 13.5 | 45.3 | |
Leica Biosystems & Microsystems — U.S. Federal Contracts($M) | 6.72 | 2.95 | 3.08 | 1.70 | 2.76 | 1.80 | 1.61 | 2.95 | 5.46 | 2.11 | 2.92 | 3.21 | |
SCIEX — U.S. Federal Contracts (mass spectrometry systems for FDA/EPA/NIH/DoD)($M) | 8.82 | 0.73 | 0.53 | 0.32 | 4.14 | 2.36 | 0.18 | 0.25 | 6.61 | 5.13 | 1.12 | 0.46 | |
Cytiva (Global Life Sciences Solutions) — U.S. Federal Contracts (BARDA / HHS / NIH)($M) | 0.94 | 0.25 | 0.05 | 0.12 | 0.59 | 0.48 | 0.22 | 0.29 | 1.16 | 0.82 | -19.8 | 0.69 | |
Masimo Corporation — U.S. Federal Contracts($M) | 0.03 | 0.14 | 0.69 | 0.33 | 0.64 | 0.47 | 0.30 | 0.36 | 1.19 | 1.22 | 0.68 | 0.72 | |
Integrated DNA Technologies (IDT) — U.S. Federal Contracts($M) | 0.10 | 0.20 | 0.02 | 0 | 0.09 | 0.15 | 0.02 | 0.02 | -1.08 | -0.33 | 0.15 | -0.03 | |
Total U.S. Medical & Diagnostic Laboratories Industry Revenue (U.S. Census Bureau QSS — NAICS 6215 Medical & Diagnostic Laboratories)($M) | 20,528 | 19,569 | 19,997 | 19,677 | 19,718 | 18,722 | 19,104 | 18,893 | 18,483 | 17,963 | 17,943 | ||
Total U.S. Taxable Hospitals Industry Revenue (U.S. Census Bureau QSS — NAICS 622 Hospitals)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Consolidated Revenue — GAAP($M)13 | 6,554 | 6,265 | 5,951 | 6,838 | 6,053 | 5,936 | 5,741 | 6,538 | 5,798 | 5,743 | 5,796 | 6,405 | |
Cost of Sales($M) | 2,717 | 2,654 | 2,360 | 2,872 | 2,530 | 2,413 | 2,230 | 2,648 | 2,397 | 2,315 | 2,309 | 2,626 | |
Gross Profit($M) | 3,837 | 3,611 | 3,591 | 3,966 | 3,523 | 3,523 | 3,511 | 3,890 | 3,401 | 3,428 | 3,487 | 3,779 | |
R&D Expense($M) | 433 | 412 | 387 | 438 | 378 | 403 | 379 | 442 | 383 | 391 | 368 | 407 | |
SG&A Expense($M) | 2,159 | 2,072 | 1,860 | 2,026 | 1,991 | 2,360 | 1,858 | 2,023 | 2,060 | 1,869 | 1,807 | 2,035 | |
Operating Profit — GAAP($M) | 1,245 | 1,127 | 1,344 | 1,502 | 1,154 | 760 | 1,274 | 1,425 | 958 | 1,168 | 1,312 | 1,337 | |
Interest Expense($M) | 135 | 107 | 63 | 55 | 67 | 71 | 72 | 61 | 87 | 65 | 65 | 85 | |
Earnings Before Income Taxes($M) | 1,132 | 1,078 | 1,235 | 1,373 | 1,076 | 655 | 1,129 | 1,315 | 977 | 1,083 | 1,271 | 1,232 | |
Income Taxes($M) | -75 | 208 | 206 | 190 | 168 | 100 | 175 | 229 | 159 | 176 | 183 | 111 | |
Net Earnings — GAAP($M) | 1,235 | 870 | 1,029 | 1,197 | 908 | 555 | 954 | 1,086 | 818 | 907 | 1,088 | 1,079 | |
EPS pha loãng (Diluted Net Earnings Per Share — GAAP)($) | 1.75 | 1.23 | 1.45 | 1.27 | 0.77 | 1.32 | 1.12 | 1.22 | 1.45 | 1.45 | |||
Basic Net Earnings Per Share — GAAP($) | 1.75 | 1.23 | 1.45 | 1.28 | 0.77 | 1.33 | 1.13 | 1.23 | 1.47 | 1.46 | |||
Weighted-Average Diluted Shares(M) | 707 | 708 | 711 | 714 | 719 | 721 | 729 | 742 | 749 | ||||
Weighted-Average Basic Shares(M) | 704 | 705 | 708 | 711 | 717 | 716 | 723 | 738 | 741 | ||||
Total Assets($M)9 | 93,281 | 92,367 | 83,544 | 83,464 | 79,897 | 81,620 | 79,116 | 77,542 | 80,615 | 78,555 | 83,402 | 84,488 | |
Cash and Cash Equivalents($M) | 5,682 | 4,348 | 5,701 | 4,615 | 1,528 | 2,957 | 1,993 | 2,078 | 2,627 | 2,374 | 7,031 | 5,864 | |
Accounts Receivable, Net($M) | 4,126 | 3,965 | 3,819 | 3,913 | 3,755 | 3,564 | 3,506 | 3,537 | 3,507 | 3,298 | 3,379 | 3,922 | |
Total Inventories($M) | 3,134 | 3,260 | 2,608 | 2,489 | 2,674 | 2,689 | 2,532 | 2,330 | 2,678 | 2,671 | 2,645 | 2,594 | |
Property, Plant and Equipment, Net($M) | 5,773 | 5,825 | 5,468 | 5,531 | 5,376 | 5,309 | 5,110 | 4,990 | 4,843 | 4,643 | 4,562 | 4,553 | |
Goodwill (increased to $48.887M after Masimo merger)($M) | 47,315 | 47,414 | 42,765 | 43,151 | 42,948 | 42,991 | 41,657 | 40,497 | 42,173 | 40,805 | 40,846 | 41,608 | |
Other Intangible Assets, Net (increased to $23.803M after Masimo merger)($M) | 21,052 | 21,358 | 17,166 | 17,817 | 18,097 | 18,629 | 18,885 | 18,568 | 19,854 | 19,545 | 19,888 | 20,746 | |
Short-Term Debt & Current Portion of Long-Term Debt (Due Within 1 Year)($M) | 2,094 | 1,411 | 923 | 2 | 23 | 502 | 501 | 505 | 1,200 | 701 | 1,746 | 1,695 | |
Long-Term Debt($M) | 24,388 | 25,147 | 17,561 | 18,416 | 16,833 | 16,853 | 15,976 | 15,500 | 16,324 | 16,309 | 16,417 | 16,707 | |
Total Stockholders' Equity($M) | 53,621 | 52,581 | 52,949 | 52,534 | 51,071 | 52,334 | 50,849 | 49,543 | 51,299 | 49,897 | 53,442 | 53,486 | |
Operating Cash Flow — GAAP($M)1 | 1,886 | 1,534 | 1,322 | 2,117 | 1,662 | 1,338 | 1,299 | 2,019 | 1,513 | 1,417 | 1,739 | 1,619 | |
Capital Expenditures($M) | 255 | 269 | 237 | 371 | 292 | 248 | 245 | 516 | 298 | 287 | 291 | 434 | |
59 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Currency unit: Millions of USD (usd_m), except EPS/median compensation in USD (usd), headcount/facilities/permits/units shipped in units (count), shares in millions of shares (millions).
- Danaher accounting periods: Fiscal year ends 31/12; quarters Q1, Q2, Q3 end on the Friday closest to the calendar quarter-end (Q3 2026 ended 25/09/2026).
- Calculation rules: The table does not calculate margins, proportions, or growth rates. The only derivation applied is period separation for Q4 = Full Year (10-K) − 9 Months (10-Q Q3) and cash flow derivation from year-to-date figures (YTD − prior YTD). Danaher reports consolidated financial statements under US GAAP and does not issue standalone parent-company statements, so no Consolidated − Standalone deduction is applied.
- Reporting cycle Q1–Q3 + Full Year: MD&A textual disclosure metrics in 10-Q/10-K (High-Growth Markets revenue share and growth, Diagnostics China VBP pricing impact, depreciation and amortization as a percentage of segment revenue) are only published for Q1, Q2, Q3 (10-Q) and Full Year (10-K); there is no standalone Q4 MD&A report.
- Restructuring & Acquisitions: (1) On 30/09/2023, Danaher completed the spin-off of the Environmental & Applied Solutions segment into Veralto Corporation (figures from 2022 onward were retrospectively adjusted by the company to continuing operations across 3 segments: Biotechnology, Life Sciences, Diagnostics). (2) On 10/06/2026, Danaher completed the acquisition of 100% of Masimo Corporation ($9.8 billion USD) and consolidated it into the Diagnostics segment; standalone SEC filings for Masimo are presented separately through its final standalone period FY2026Q1.
Không hiện vì thiếu các kỳ gần đây (11)
- Global Suppliers (>50,000 / >48,000 / >45,000) — Only disclosed as lower-bound estimates (>62,000 in 2022, >50,000 in 2023, >48,000 in 2024, >45,000 in 2025) — excluded.
- Speak Up! Reports Received and Investigated (>1,000 / >1,220 / >1,200 / >1,300) — Total absolute reports only stated as approximate figures (>1,200, >1,300); retained exact normalized rate of 1.9 reports / 100 associates.
- Languages Spoken (>20), Associates 18–20 Years Old (<1%), Bonus Participation (>90%) — Only disclosed as approximate figures (>20 languages, <1%, >90%) — excluded.
- GHG Scope 3 Emissions & Categories 1–15 (3,504,063 tCO2e) — Comprehensive inventory only disclosed for a single year (FY2024 = 3,504,063 tCO2e; FY2023 and FY2025 blank '—'), lacking 2 consecutive years.
- EEO-1 U.S. Workforce Race/Ethnicity × Gender Matrix (22,953 U.S. associates) — Danaher's website currently publicly hosts only the 2024 EEO-1 report (a single annual period, lacking continuous FY2025/FY2023 data) — excluded.
- Tariff Refund Impact on Operating Margin (Total Company, %) — occurred in 1 period only, FY2026Q2
- Tariff Refund Impact on Operating Margin (Biotechnology, %) — occurred in 1 period only, FY2026Q2
- Tariff Refund Impact on Operating Margin (Life Sciences, %) — occurred in 1 period only, FY2026Q2
- Tariff Refund Impact (%) — only incurred in 1 period, FY2026Q2
- Quarterly Price Realization for Total Company, Biotechnology & Life Sciences (Quarterly Price Realization %) — in certain quarters (such as Q1/Q3 2026), the company only qualitatively stated 'did not have a significant impact' in the 10-Q, thus lacking 3 consecutive quarterly data points (retained the FY2022–FY2025 10-K annual series and the Diagnostics quarterly series with complete data points).
- Diagnostics Core Revenue Growth Excluding Cepheid Respiratory (Diagnostics Core Growth ex-Respiratory %) — only disclosed in Q2 & Q3 2026 earnings calls/presentations (2 quarters), lacking 3 consecutive quarters (retained the Total Company Core Growth ex-Respiratory series with 7 consecutive quarters FY2025Q1–FY2026Q3).
Dữ liệu cập nhật 2026-11-02.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core Sales Growth Drivers, Cepheid Respiratory Testing, Pricing & Backlog
- Total Company Core Sales Growth (Non-GAAP) (%)20 kỳ
- Biotechnology — Core Sales Growth (%) (%)20 kỳ
- Life Sciences — Core Sales Growth (%) (%)20 kỳ
- Diagnostics — Core Sales Growth (%) (%)20 kỳ
- Cepheid Respiratory Testing Revenue (GeneXpert 4-in-1 & COVID-19) ($M)15 kỳ
- High-Growth Markets % of Total Sales (%)18 kỳ
- Remaining Performance Obligations / Unfulfilled Backlog ($M)35 kỳ
- Total Contract Liabilities — Current & Noncurrent ($M)35 kỳ
2-Dimensional Revenue Breakdown Matrix (Segment × Recurring Consumables / Equipment, Geographic Region, Leasing & Country)
- Consolidated Recurring Revenue (Consumables, Reagents, Services & OTL Leases) ($M)15 kỳ
- Consolidated Nonrecurring Revenue (Nonrecurring Revenue — Laboratory/Hospital Equipment Systems and Machinery) ($M)15 kỳ
- Equipment Lease Revenue — OTLs & STLs ($M)18 kỳ
- North America Revenue — Consolidated ($M)15 kỳ
- Western Europe Revenue — Consolidated ($M)15 kỳ
- Other Developed Markets (Japan, Australia, South Korea) Revenue — Consolidated ($M)15 kỳ
- High-Growth Markets (China, India, Latin America, Eastern Europe, Middle East) Revenue — Consolidated ($M)15 kỳ
- United States Sales — 10-K Note Geographical Areas ($M)5 kỳ
- China Sales — 10-K Note Geographical Areas ($M)5 kỳ
- All Other Countries Sales — 10-K ($M)5 kỳ
Adjusted Segment Profitability, ASU 2023-07 Expense Structure, Cash Flow Conversion & Operating Assets
- Adjusted Operating Profit — Non-GAAP ($M)19 kỳ
- Consolidated Adjusted EBITDA (Non-GAAP Supplemental Data) ($M)19 kỳ
- Segment Intangibles Amortization ($M)19 kỳ
- Segment Depreciation ($M)19 kỳ
- Other Segment Items Under ASU 2023-07 — Total 3 Segments ($M)7 kỳ
- Adjusted Gross Profit Margin — Non-GAAP (%)10 kỳ
- Adjusted R&D — Non-GAAP ($M)10 kỳ
- Adjusted SG&A — Non-GAAP ($M)10 kỳ
- Adjusted Net Earnings — Non-GAAP ($M)10 kỳ
- Free Cash Flow — Non-GAAP ($M)16 kỳ
- Finished Goods Inventory ($M)24 kỳ
- Work in Process Inventory ($M)24 kỳ
- Raw Materials Inventory ($M)24 kỳ
- Customer-Leased Equipment Gross PP&E — Reagent-Rental Installed Fleet ($M)4 kỳ
- Consolidated Amortization of Intangible Assets — XBRL ($M)26 kỳ
- Operating Lease Cost ($M)7 kỳ
Self-Disclosed Subsidiary: Masimo Corporation (CIK 0000937556 — Merged into Diagnostics Segment on 10/06/2026)
UK Self-Disclosed Subsidiaries: 6 Operating Entities (Abcam, Cytiva, Pall, Leica Biosystems — FY2017–FY2025)
- Abcam PLC (Life Sciences Subsidiary — Antibodies & Proteomics Reagents, Company #03509322) — Median Hourly Pay Gap (%)9 kỳ
- Global Life Sciences Solutions Operations UK Ltd / Cytiva UK Ops (Biotechnology, Company #12063780) — Median Hourly Pay Gap (%)6 kỳ
- Global Life Sciences Solutions Manufacturing UK Ltd / Cytiva UK Mfg (Biomanufacturing, Company #12063741) — Median Hourly Pay Gap (%)5 kỳ
- Pall Europe Limited (Bio & Industrial Filtration Subsidiary, Company #07211681) — Median Hourly Pay Gap (%)8 kỳ
- Pall Manufacturing UK Limited (Pall Filtration Membrane Manufacturing Plant in the UK, Company #00769075) — Median Hourly Pay Gap (%)8 kỳ
- Leica Biosystems Newcastle Limited (Histopathology/IHC Diagnostic R&D & Manufacturing Center, Company #02163063) — Median Hourly Pay Gap (%)6 kỳ
Biomedical Equipment Quality (FDA/ISO), Global Workforce, Supply Chain, Safety & Environment (FY2020–FY2025)
- FDA-Registered Sites — Total4 kỳ
- FDA Form 483 Inspectional Observations4 kỳ
- Company-Reported Total FDA Product Recalls4 kỳ
- Global Associates — Exact Count in Sustainability Supplemental Data4 kỳ
- Total External New Hires4 kỳ
- Total Associate Turnover Rate (%)4 kỳ
- CEO Pay Ratio — DEF 14A Proxy Statement (×)2 kỳ
- Annual Supplier Spend ($B) ($M)4 kỳ
- Total Recordable Incident Rate per 100 Employees (TRIR) (×)4 kỳ
- Manufacturing / Operating Facilities Certified to ISO 140014 kỳ
- Total Energy Consumption (MWh)3 kỳ
- Scope 1 + Scope 2 Market-Based GHG Emissions (thousand metric tons CO2e)4 kỳ
- Total Waste Generated (metric tons)4 kỳ
Independent Regulatory Agencies, Clinical Trials, U.S. Federal Contracts & Industry Indicators Data (Monthly / Quarterly / Annual)
- openFDA — Total FDA 510(k) Medical Device Clearances for the Danaher Ecosystem (Monthly / Quarterly / Annual)130 kỳ
- openFDA — Total FDA PMA (Premarket Approval & Supplements) High-Risk Device Approvals for the Danaher Ecosystem116 kỳ
- openFDA — Device Recall Events for the Danaher Ecosystem on the FDA Portal105 kỳ
- openFDA — MAUDE Adverse Event Reports for the Danaher Ecosystem141 kỳ
- ClinicalTrials.gov — Lead-Sponsor Trials Started10 kỳ
- USAspending.gov — Federal Contract Obligations ($M)117 kỳ
- U.S. Producer Price Index (BLS PPI) — In-Vitro Diagnostic Substance Manufacturing (NAICS 325413 — Diagnostics Segment Benchmark) (×)129 kỳ
- U.S. Producer Price Index (BLS PPI) — Biological Product Manufacturing (NAICS 325414 — Biotechnology Segment Benchmark) (×)129 kỳ
- U.S. Producer Price Index (BLS PPI) — Analytical Laboratory Instrument Manufacturing (NAICS 334516 — Life Sciences Segment Benchmark) (×)129 kỳ
- U.S. Producer Price Index (BLS PPI) — Surgical and Medical Instrument Manufacturing (NAICS 339112) (×)129 kỳ
- Total U.S. Medical & Diagnostic Laboratories Industry Revenue (U.S. Census Bureau QSS — NAICS 6215 Medical & Diagnostic Laboratories) ($M)42 kỳ
- Total U.S. Taxable Hospitals Industry Revenue (U.S. Census Bureau QSS — NAICS 622 Hospitals) ($M)42 kỳ
Financial Statement & Segment Context (+ Q3 2026 XBRL Patch)
- Biotechnology — GAAP Revenue ($M)18 kỳ
- Life Sciences — GAAP Revenue ($M)43 kỳ
- Diagnostics — GAAP Revenue ($M)43 kỳ
- Environmental & Applied Solutions (Legacy FY2009–FY2023Q3 — spun off as Veralto Corp on 30/09/2023) — Revenue ($M)51 kỳ
- Dental (Legacy FY2009–FY2019 — spun off as Envista Holdings in 2019) — Revenue ($M)35 kỳ
- Consolidated Revenue — GAAP ($M)72 kỳ
- Total Assets ($M)70 kỳ
- Operating Cash Flow — GAAP ($M)71 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Danaher
- Danaher SEC 10-Q (2026Q3, filed 2026-10-21) ↗
- Danaher SEC 10-K (FY2025, filed 2026-02-24) ↗
- Danaher IR — nongaap_2026Q3 ↗
- Danaher IR — nongaap_2025Q4 ↗
- Danaher IR — esg_2026_report ↗
- U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
- UK Government Gender Pay Gap Service (FY2025) ↗
- Masimo SEC 10-Q (2026Q1, filed 2026-05-05) ↗
- Masimo SEC 10-K (FY2025, filed 2026-02-27) ↗
- U.S. Treasury USAspending.gov API (Federal Contract Obligations) ↗
- Danaher SEC DEF 14A (FY2025, filed 2026-03-25) ↗
- NIH ClinicalTrials.gov API v2 (Lead-Sponsor Study Registry) ↗
See a number that looks wrong?